Carol D. Hamilton

Jason E. Stout2
David P. Holland2
Kathryn E Lancaster1
2Jason E. Stout
2David P. Holland
1Kathryn E Lancaster
1Giuseppe Novelli
Learn More
  • Gerard A. J. Morris, Digna R. Velez Edwards, Philip C. Hill, Christian Wejse, Cyrille Bisseye, Rikke Olesen +17 others
  • 2011
We examined whether polymorphisms in interleukin-12B (IL12B) associate with susceptibility to pulmonary tuberculosis (PTB) in two West African populations (from The Gambia and Guinea-Bissau) and in two independent populations from North and South America. Nine polymorphisms (seven SNPs, one insertion/deletion, one microsatellite) were analyzed in 321 PTB(More)
BACKGROUND The optimal treatment for latent multiple-drug resistant tuberculosis infection remains unclear. In anticipation of future clinical trials, we modeled the expected performance of six potential regimens for treatment of latent multiple-drug resistant tuberculosis. METHODS A computerized Markov model to analyze the total cost of treatment for six(More)
  • Elizabeth A Reddy, Boniface N Njau, Susan C Morpeth, Kathryn E Lancaster, Alison C Tribble, Venance P Maro +12 others
  • 2014
BACKGROUND Routine tuberculosis culture remains unavailable in many high-burden areas, including Tanzania. This study sought to determine the impact of providing mycobacterial culture results over standard of care [unconcentrated acid-fast (AFB) smears] on management of persons with suspected tuberculosis. METHODS Adults and children with suspected(More)
RATIONALE Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability. OBJECTIVES To inform clinical trial design by estimating the potential costs and effectiveness of rifapentine-based regimens for(More)
  • 1